



26 13

IN THE UNITED STATES PATENTS AND TRADEMARK OFFICE

In re the application of: Feng et al.

U.S. Serial No.: 10/525,410

Confirmation No.: 8315

Filed: January 26, 2005

Group Art Unit: 2613

Examiner: NYA

For: NOVEL BENZODIFURANIMIDAZOLINE
AND BENZOFURANIMIDAZOLINE DERIVATIVES
AND THEIR USE FOR THE TREATMENT OF GLAUCOMA

**REQUEST FOR CORRECTION
OF FILING RECEIPT**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450.

Sir:

Applicants respectfully request correction of the filing receipt received in the above-referenced application to reflect that the application was given the filing date of January 26, 2005, instead of January 28, 2005, as reflected in the Decision on Petition Under 37 CFR 1.137(b) dated July 8, 2005 (copy attached).

Respectfully submitted,

ALCON


8/24/05

Date

Patrick M. Ryan

Patrick M. Ryan
Reg. No. 36,263

Address for Correspondence:
Alcon Research, Ltd.
R&D Counsel Q-148
6201 South Freeway
Fort Worth, TX 76134-2099
(817) 551-3066
Docket: 2345






08 JUL 2005

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. Box 1450
ALEXANDRIA, VA 22313-1450
www.uspto.gov

Alcon Research
Attn: Barry L Copeland
6201 South Freeway
Fort Worth TX 76134-2099



RECEIVED

JUL 11 2005

PMR

In re Application of
FENG, Zixia et al.

Application No.: 10/525,410

PCT No.: PCT/US02/39316

Int. Filing Date: 09 December 2002

Priority Date: 20 December 2001

Docket No.: 2345F USA

For: NOVEL ... TREATMENT OF
GLAUCOMA

DECISION

ON PETITION UNDER

37 CFR 1.137(b)

Applicants' "Petition to Revive Under 37 C.F.R. §1.137(b)," filed in the above-captioned application on 30 June 2005 is **GRANTED**. It was accompanied by a postcard receipt indicating that a petition to revive was received by the Office on 05 April 2005. Applicants indicated that the accompanying petition is a copy of the 05 April 2005 petition. The 30 June 2005 petition is accepted as having a receipt date of 05 April 2005.

Applicants state that the entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional, as required by 37 CFR 1.137(b)(3). A terminal disclaimer is not required as the application was filed on or after 08 June 1995. Accordingly, all requirements under 37 CFR 1.137(b) have been satisfied.

A declaration in compliance with 37 CFR 1.497(a)-(b) has been submitted. The fee for late filing of the oath or declaration has been paid.

The transmittal letter accompanying this application has a new correspondence address, but it is not accompanied by a power of attorney, authorizing the change.

This application is being forwarded to the National Stage Processing Branch of the Office of PCT Operations for continued processing in accordance with this decision. The application has a date of 26 January 2005 under 35 U.S.C. §§371(c)(1), (c)(2) and (c)(4).

Erin P. Thomson

Erin P. Thomson
Attorney Advisor
PCT Legal Administration

Telephone: 571-272-3292
Facsimile: 571-273-0459

cc: Kilyk & Bowersox PLLC
53 A East Lee Street
Warrenton, VA 20136